https://www.pharmacytimes.com/view/ims-2025-pharmacist-role-in-optimizing-outcomes-with-elranatamab
Pharmacists enhance patient care in multiple myeloma by focusing on infection prevention, CRS management, and optimizing outcomes with T-cell engagers post-CAR...
imspharmacistroleoptimizingoutcomes
https://www.pharmaceutical-technology.com/data-insights/elranatamab-pfizer-multiple-myeloma-kahler-disease-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-186194&utm_campaign=recommended-articles-pi
Elranatamab is under clinical development by Pfizer and currently in Phase III for Multiple Myeloma (Kahler Disease).
multiple myelomakahler diseaseelranatamabpfizerlikelihood
https://www.pharmacytimes.com/view/elranatamab-plus-daratumumab-and-lenalidomide-yields-durable-responses-manageable-safety
Elranatamab combined with daratumumab and lenalidomide shows promising results for treating newly diagnosed multiple myeloma, enhancing patient outcomes.
elranatamabplusdaratumumablenalidomideyields